DTIL

Precision BioSciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-12

Figures on this page computed 2026-11-08 12:40 UTC

Last close

8.12USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-12

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001628280-26-017019
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-12
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-017019
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-11-03
The filing itself
-133.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-017019
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
The filing itself
-192.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-017019
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001628280-26-017019
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-11-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.22 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.24x

0.88x

1.40x

n/a

0.07x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-12

Sales0.24x
Its own average over 10 years, 141.1M.
Profit0.88x
Its own average over 10 years, -51.9M.
Free cash flow1.40x
Its own average over 10 years, -46.9M.
Debtn/a
Its own average over 2 years, 17.0M.
Price0.07x
Its own average over 8 years, 122. Market data, 2026-11-04

Price is furthest from its own average, at 0.07 times.

Sales is 0.24 times its own 10-year average; Profit is 0.88 times its own 10-year average; Free cash flow is 1.40 times its own 10-year average; Price is 0.07 times its own 8-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-12

Sales against its own 10-year average0.24
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-017019
Reported in
USD
The filing itself
Profit against its own 10-year average0.88
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-017019
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.40
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-017019
Reported in
USD
The filing itself
Debt against its own 2-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-017019
Reported in
USD
The filing itself
Price against its own 8-year average0.07Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD